Proteus Digital Health Announces New Chairman of the Board and Chief Commercial Officer
Leading Digital Medicines Company Strengthens Customer and Corporate Governance Capabilities to Advance Commercialization
NOVEMBER 17, 2015, REDWOOD CITY, CA—Proteus Digital Health™ announced three executive appointments in order to propel the company’s commercialization and infrastructure for growth. Healthcare industry veteran Molly O’Neill joins the executive team as Chief Commercial Officer, Jonathan Symonds CBE, Chairman of HSBC Bank PLC, is appointed to Chairman of the Board and Shumeet Banerji, Ph.D., is appointed to the company’s Board of Directors.
In her role as Chief Commercial Officer, O’Neill will lead partnerships with major health systems, payers and key provider customers in the United States. O’Neill brings over 30 years of experience in developing growth strategies to increase market share and revenues of academic, not for profit and investor owned health care institutions. O’Neill comes to Proteus from Tenet Health, a diversified healthcare services company, where she served on the management team as senior vice president of business development.
Jonathan Symonds is Chairman of HSBC Bank Plc, Chairman of the Supervisory Board of Innocoll AG and Non-executive Director of Genomics England. Formerly, Symonds was Chief Financial Officer of Novartis, Partner and Managing Director of Goldman Sachs and Chief Financial Officer of AstraZeneca Plc. Symonds has served on the Proteus Board of Directors since June of 2014 and will continue advising the company on strategy, financial management and corporate governance in his new role as Chairman.
Shumeet Banerji, Ph.D., is founder and partner of Condorcet, LP an investment and advisory firm. Banerji retired from Booz & Company Inc. in 2013 having served as its founding Chief Executive Officer. He formerly held leadership roles at Booz, Allen & Hamilton in India, the U.K., Europe and globally, where he advised public and private sector entities at the Board level. He serves on the Board of HP, Inc. and Innocoll, AG. Banerji will provide oversight on Proteus’ corporate strategy and operational performance among other topics of critical importance to the company.
“Molly is ideally suited to engage both existing and new customers who are ready to embark on a transformational journey in healthcare and Jon and Shumeet have already provided essential corporate strategy and financial management counsel to the company,” said Andrew Thompson, President and CEO of Proteus Digital Health. “The commercial and financial expertise that these individuals bring to the company will enable Proteus to commercialize Digital Medicines at scale.”
About Proteus Digital Health®
Proteus is creating a new category of therapy: Digital Medicines. Digital Medicine therapy includes drugs that communicate when they’ve been taken, wearable sensors that capture physiologic response, applications that support patient self-care and physician decision making, and data analytics to serve the needs of doctors and health systems. The goal of Digital Medicines is to empower patients and their families, enable physicians and health systems to more effectively manage risk and ensure that outcomes are reliably achieved. Proteus received FDA market clearance in the United States and a CE mark in Europe for its wearable and Ingestible Sensor devices. Headquartered in Redwood City, Calif., Proteus is privately held and funded by leading institutional and corporate investors, including:, Novartis, Otsuka, Oracle and Kaiser Permanente. For more information, visit www.proteus.com.
Proteus Digital Health